OA10744A - Controlled release of miotic and mydriatic drugs in the anterior chamber - Google Patents

Controlled release of miotic and mydriatic drugs in the anterior chamber Download PDF

Info

Publication number: OA10744A
Authority: OA; OAPI
Prior art keywords: composition; polymer; miotic; agent; agents
Prior art date: 1995-04-18

Application number

OA70111A

Other languages

English (en)

Inventor

Miles A Galin

Joseph C Salam-One

Stanley C Israel

Original Assignee

Miles A Galin

Joseph C Salam-One

Stanley C Israel

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-04-18

Filing date

1997-10-17

Publication date

2002-12-11

1997-10-17 Application filed by Miles A Galin, Joseph C Salam-One, Stanley C Israel filed Critical Miles A Galin

2002-12-11 Publication of OA10744A publication Critical patent/OA10744A/en

Links

230000003547 miosis Effects 0.000 title claims abstract description 30
210000002159 anterior chamber Anatomy 0.000 title claims abstract description 25
229940079593 drug Drugs 0.000 title description 32
239000003814 drug Substances 0.000 title description 32
230000002911 mydriatic effect Effects 0.000 title description 8
238000013270 controlled release Methods 0.000 title description 2
239000000203 mixture Substances 0.000 claims abstract description 70
229920000642 polymer Polymers 0.000 claims abstract description 49
239000002637 mydriatic agent Substances 0.000 claims abstract description 32
239000003604 miotic agent Substances 0.000 claims abstract description 30
239000003094 microcapsule Substances 0.000 claims abstract description 15
238000001356 surgical procedure Methods 0.000 claims abstract description 15
239000000693 micelle Substances 0.000 claims abstract description 11
229920001577 copolymer Polymers 0.000 claims abstract description 7
239000003795 chemical substances by application Substances 0.000 claims description 35
QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical group C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 claims description 18
QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 claims description 18
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims description 15
238000000034 method Methods 0.000 claims description 14
229930003347 Atropine Natural products 0.000 claims description 13
229960000396 atropine Drugs 0.000 claims description 13
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims description 13
229960001416 pilocarpine Drugs 0.000 claims description 13
SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims description 11
229960001802 phenylephrine Drugs 0.000 claims description 11
229920002385 Sodium hyaluronate Polymers 0.000 claims description 10
125000000129 anionic group Chemical group 0.000 claims description 10
125000002091 cationic group Chemical group 0.000 claims description 10
229940010747 sodium hyaluronate Drugs 0.000 claims description 10
YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical group [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 10
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 7
229920002674 hyaluronan Polymers 0.000 claims description 7
229960003160 hyaluronic acid Drugs 0.000 claims description 7
HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical group [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 claims description 6
229960002028 atropine sulfate Drugs 0.000 claims description 6
RNAICSBVACLLGM-GNAZCLTHSA-N pilocarpine hydrochloride Chemical group Cl.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C RNAICSBVACLLGM-GNAZCLTHSA-N 0.000 claims description 6
229960002139 pilocarpine hydrochloride Drugs 0.000 claims description 6
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical group FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 4
229920001287 Chondroitin sulfate Polymers 0.000 claims description 4
JUGOREOARAHOCO-UHFFFAOYSA-M acetylcholine chloride Chemical group [Cl-].CC(=O)OCC[N+](C)(C)C JUGOREOARAHOCO-UHFFFAOYSA-M 0.000 claims description 4
230000002378 acidificating effect Effects 0.000 claims description 4
229940059329 chondroitin sulfate Drugs 0.000 claims description 4
RNAICSBVACLLGM-KXNXZCPBSA-N (3r,4r)-3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one;hydrochloride Chemical group Cl.C1OC(=O)[C@H](CC)[C@H]1CC1=CN=CN1C RNAICSBVACLLGM-KXNXZCPBSA-N 0.000 claims description 3
OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical group [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 claims description 3
229960003733 phenylephrine hydrochloride Drugs 0.000 claims description 3
DMKKMGYBLFUGTO-UHFFFAOYSA-N 2-methyloxirane;oxirane Chemical compound C1CO1.C1CO1.CC1CO1 DMKKMGYBLFUGTO-UHFFFAOYSA-N 0.000 claims description 2
229920001400 block copolymer Polymers 0.000 claims description 2
229920000747 poly(lactic acid) Polymers 0.000 claims description 2
208000035657 Abasia Diseases 0.000 claims 1
238000013268 sustained release Methods 0.000 abstract description 9
239000012730 sustained-release form Substances 0.000 abstract description 9
230000001404 mediated effect Effects 0.000 abstract description 5
230000003993 interaction Effects 0.000 abstract description 4
230000002459 sustained effect Effects 0.000 abstract description 4
239000000243 solution Substances 0.000 description 12
WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 8
GIKNHHRFLCDOEU-UHFFFAOYSA-N 4-(2-aminopropyl)phenol Chemical compound CC(N)CC1=CC=C(O)C=C1 GIKNHHRFLCDOEU-UHFFFAOYSA-N 0.000 description 8
229940014041 hyaluronate Drugs 0.000 description 8
239000007943 implant Substances 0.000 description 7
PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 6
BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 6
229960001697 physostigmine Drugs 0.000 description 6
PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 6
210000001747 pupil Anatomy 0.000 description 6
229960004791 tropicamide Drugs 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
210000001742 aqueous humor Anatomy 0.000 description 5
STECJAGHUSJQJN-VJQRDGCPSA-N chembl3084722 Chemical compound C1([C@@H](CO)C(=O)O[C@@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-VJQRDGCPSA-N 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
238000012377 drug delivery Methods 0.000 description 5
229960002646 scopolamine Drugs 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
206010053317 Hydrophobia Diseases 0.000 description 4
229930195725 Mannitol Natural products 0.000 description 4
229960004484 carbachol Drugs 0.000 description 4
AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 4
230000000694 effects Effects 0.000 description 4
229950005360 hydroxyamfetamine Drugs 0.000 description 4
239000000594 mannitol Substances 0.000 description 4
235000010355 mannitol Nutrition 0.000 description 4
230000007935 neutral effect Effects 0.000 description 4
230000007306 turnover Effects 0.000 description 4
229930000680 A04AD01 - Scopolamine Natural products 0.000 description 3
208000002177 Cataract Diseases 0.000 description 3
ZTVIKZXZYLEVOL-MCOXGKPRSA-N Homatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(O)C1=CC=CC=C1 ZTVIKZXZYLEVOL-MCOXGKPRSA-N 0.000 description 3
STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 3
STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
229960001815 cyclopentolate Drugs 0.000 description 3
SKYSRIRYMSLOIN-UHFFFAOYSA-N cyclopentolate Chemical compound C1CCCC1(O)C(C(=O)OCCN(C)C)C1=CC=CC=C1 SKYSRIRYMSLOIN-UHFFFAOYSA-N 0.000 description 3
238000000502 dialysis Methods 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
OVXQHPWHMXOFRD-UHFFFAOYSA-M ecothiopate iodide Chemical compound [I-].CCOP(=O)(OCC)SCC[N+](C)(C)C OVXQHPWHMXOFRD-UHFFFAOYSA-M 0.000 description 3
229960000857 homatropine Drugs 0.000 description 3
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
230000007774 longterm Effects 0.000 description 3
238000012423 maintenance Methods 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
PRZXEPJJHQYOGF-KXNXZCPBSA-N (3r,4r)-3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one;nitric acid Chemical compound O[N+]([O-])=O.C1OC(=O)[C@H](CC)[C@H]1CC1=CN=CN1C PRZXEPJJHQYOGF-KXNXZCPBSA-N 0.000 description 2
WTRRIQCGCGCMQA-CBZIJGRNSA-N 3-Hydroxyestra-1,3,5(10),6-tetraen-17-one Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3C=CC2=C1 WTRRIQCGCGCMQA-CBZIJGRNSA-N 0.000 description 2
RZCJLMTXBMNRAD-UHFFFAOYSA-N 4-(2-aminopropyl)phenol;hydrobromide Chemical compound Br.CC(N)CC1=CC=C(O)C=C1 RZCJLMTXBMNRAD-UHFFFAOYSA-N 0.000 description 2
YKFROQCFVXOUPW-UHFFFAOYSA-N 4-(methylthio) aniline Chemical compound CSC1=CC=C(N)C=C1 YKFROQCFVXOUPW-UHFFFAOYSA-N 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
GSYQNAMOFFWAPF-IILNCVEESA-N LSM-1606 Chemical compound C1([C@@H](CO)C(=O)OC2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)([O-])C)=CC=CC=C1 GSYQNAMOFFWAPF-IILNCVEESA-N 0.000 description 2
PPVPUWFOCLLNKS-UHFFFAOYSA-N N-(1-phenylpropan-2-yl)hydroxylamine hydroiodide Chemical compound I.ONC(C)CC1=CC=CC=C1 PPVPUWFOCLLNKS-UHFFFAOYSA-N 0.000 description 2
LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
FRMDDIJBLQNNTC-MOTQWOLNSA-N [(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 2-hydroxy-2-phenylacetate;hydrochloride Chemical compound Cl.C([C@H]1CC[C@@H](C2)N1C)C2OC(=O)C(O)C1=CC=CC=C1 FRMDDIJBLQNNTC-MOTQWOLNSA-N 0.000 description 2
YYBNDIVPHIWTPK-KYJQVDHRSA-N [(3as,8bs)-3,4,8b-trimethyl-1,2,3,3a-tetrahydropyrrolo[2,3-b]indol-3-ium-7-yl] n-methylcarbamate;sulfate Chemical compound [O-]S([O-])(=O)=O.C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CC[NH+]2C.C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CC[NH+]2C YYBNDIVPHIWTPK-KYJQVDHRSA-N 0.000 description 2
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
229940105329 carboxymethylcellulose Drugs 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
FUFVKLQESJNNAN-RIMUKSHESA-M chembl1200851 Chemical compound [Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C)C(=O)C(O)C1=CC=CC=C1 FUFVKLQESJNNAN-RIMUKSHESA-M 0.000 description 2
DWSGTFTVBLXELC-RDYJJYPNSA-N chembl1319362 Chemical compound Br.O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(O)C1=CC=CC=C1 DWSGTFTVBLXELC-RDYJJYPNSA-N 0.000 description 2
XMLNCADGRIEXPK-KUMOIWDRSA-M chembl2146143 Chemical compound [Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C)C(=O)C(CO)C1=CC=CC=C1 XMLNCADGRIEXPK-KUMOIWDRSA-M 0.000 description 2
RHKZVMUBMXGOLL-UHFFFAOYSA-N cyclopentolate hydrochloride Chemical compound Cl.C1CCCC1(O)C(C(=O)OCCN(C)C)C1=CC=CC=C1 RHKZVMUBMXGOLL-UHFFFAOYSA-N 0.000 description 2
229960000710 cyclopentolate hydrochloride Drugs 0.000 description 2
229960003715 demecarium bromide Drugs 0.000 description 2
YHKBUDZECQDYBR-UHFFFAOYSA-L demecarium bromide Chemical compound [Br-].[Br-].C=1C=CC([N+](C)(C)C)=CC=1OC(=O)N(C)CCCCCCCCCCN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 YHKBUDZECQDYBR-UHFFFAOYSA-L 0.000 description 2
SFCNPIUDAIFHRD-UHFFFAOYSA-N ditert-butyl-[[2-(ditert-butylphosphanylmethyl)phenyl]methyl]phosphane Chemical compound CC(C)(C)P(C(C)(C)C)CC1=CC=CC=C1CP(C(C)(C)C)C(C)(C)C SFCNPIUDAIFHRD-UHFFFAOYSA-N 0.000 description 2
238000001125 extrusion Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
229960002106 homatropine hydrobromide Drugs 0.000 description 2
229960003246 homatropine methylbromide Drugs 0.000 description 2
229940018465 hydroxyamphetamine hydrobromide Drugs 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
230000004410 intraocular pressure Effects 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
230000002262 irrigation Effects 0.000 description 2
238000003973 irrigation Methods 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
239000002504 physiological saline solution Substances 0.000 description 2
229960001847 physostigmine sulfate Drugs 0.000 description 2
229960001963 pilocarpine nitrate Drugs 0.000 description 2
229910001414 potassium ion Inorganic materials 0.000 description 2
229960004499 scopolamine hydrobromide Drugs 0.000 description 2
WTGQALLALWYDJH-MOUKNHLCSA-N scopolamine hydrobromide (anhydrous) Chemical compound Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 WTGQALLALWYDJH-MOUKNHLCSA-N 0.000 description 2
CXYRUNPLKGGUJF-RAFJPFSSSA-M scopolamine methobromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)C)=CC=CC=C1 CXYRUNPLKGGUJF-RAFJPFSSSA-M 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910001415 sodium ion Inorganic materials 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
XHZPRMZZQOIPDS-UHFFFAOYSA-N 2-Methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(C)(C)NC(=O)C=C XHZPRMZZQOIPDS-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
239000004956 Amodel Substances 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
229920000045 Dermatan sulfate Polymers 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
229920002971 Heparan sulfate Polymers 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
229920000288 Keratan sulfate Polymers 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
206010027646 Miosis Diseases 0.000 description 1
JQIPVEBSCXNGIG-UHFFFAOYSA-N N-ethyl-3-hydroxy-2-phenyl-N-(pyridin-4-ylmethyl)propanamide hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 JQIPVEBSCXNGIG-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229920001244 Poly(D,L-lactide) Polymers 0.000 description 1
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
241000287181 Sturnus vulgaris Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000001800 adrenalinergic effect Effects 0.000 description 1
210000003484 anatomy Anatomy 0.000 description 1
229920001586 anionic polysaccharide Polymers 0.000 description 1
150000004836 anionic polysaccharides Chemical class 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000000149 argon plasma sintering Methods 0.000 description 1
229950010917 atropine oxyde Drugs 0.000 description 1
HGWPFSBHDACWNL-LZYIFBDPSA-N atropine oxyde Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N+]2([O-])C)C(=O)C(CO)C1=CC=CC=C1 HGWPFSBHDACWNL-LZYIFBDPSA-N 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
239000000679 carrageenan Substances 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
229940113118 carrageenan Drugs 0.000 description 1
230000008859 change Effects 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
230000001713 cholinergic effect Effects 0.000 description 1
KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
230000009146 cooperative binding Effects 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
RWZVPVOZTJJMNU-UHFFFAOYSA-N demarcarium Chemical compound C=1C=CC([N+](C)(C)C)=CC=1OC(=O)N(C)CCCCCCCCCCN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 RWZVPVOZTJJMNU-UHFFFAOYSA-N 0.000 description 1
229960004656 demecarium Drugs 0.000 description 1
AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
229940051593 dermatan sulfate Drugs 0.000 description 1
MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 1
230000000916 dilatatory effect Effects 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
VICYBMUVWHJEFT-UHFFFAOYSA-N dodecyltrimethylammonium ion Chemical compound CCCCCCCCCCCC[N+](C)(C)C VICYBMUVWHJEFT-UHFFFAOYSA-N 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229960002445 echothiophate iodide Drugs 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000009963 fulling Methods 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
229940063559 methacrylic acid Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
208000001491 myopia Diseases 0.000 description 1
ALRZZAHTTYSVRF-UHFFFAOYSA-N n-(1-phenylpropan-2-yl)hydroxylamine;hydrochloride Chemical compound Cl.ONC(C)CC1=CC=CC=C1 ALRZZAHTTYSVRF-UHFFFAOYSA-N 0.000 description 1
229940037982 ophthalmologicals Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000004044 response Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
239000008154 viscoelastic solution Substances 0.000 description 1
239000003190 viscoelastic substance Substances 0.000 description 1
239000011345 viscous material Substances 0.000 description 1
210000004127 vitreous body Anatomy 0.000 description 1
239000000230 xanthan gum Substances 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
235000010493 xanthan gum Nutrition 0.000 description 1
229940082509 xanthan gum Drugs 0.000 description 1
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/048—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/08—Mydriatics or cycloplegics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Ophthalmology & Optometry (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Molecular Biology (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

OA70111A 1995-04-18 1997-10-17 Controlled release of miotic and mydriatic drugs in the anterior chamber OA10744A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/423,703 US5612027A (en)	1995-04-18	1995-04-18	Controlled release of miotic and mydriatic drugs in the anterior chamber

Publications (1)

Publication Number	Publication Date
OA10744A true OA10744A (en)	2002-12-11

Family

ID=23679887

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA70111A OA10744A (en)	1995-04-18	1997-10-17	Controlled release of miotic and mydriatic drugs in the anterior chamber

Country Status (26)

Country	Link
US (4)	US5612027A (is)
EP (1)	EP0822822A4 (is)
JP (1)	JP3314085B2 (is)
KR (1)	KR100307685B1 (is)
CN (1)	CN1181703A (is)
AP (1)	AP850A (is)
AU (1)	AU707013B2 (is)
BG (1)	BG62598B1 (is)
BR (1)	BR9608441A (is)
CA (1)	CA2216417C (is)
CZ (1)	CZ326497A3 (is)
DE (1)	DE822822T1 (is)
EA (1)	EA000790B1 (is)
EE (1)	EE9700286A (is)
ES (1)	ES2116950T1 (is)
GE (1)	GEP20002231B (is)
HU (1)	HUP9802665A3 (is)
IS (1)	IS4572A (is)
MX (1)	MX9708043A (is)
NO (1)	NO974808L (is)
NZ (1)	NZ306875A (is)
OA (1)	OA10744A (is)
PL (1)	PL322820A1 (is)
SK (1)	SK140297A3 (is)
TR (1)	TR199701192T1 (is)
WO (1)	WO1996032951A1 (is)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6090925A (en)	1993-03-09	2000-07-18	Epic Therapeutics, Inc.	Macromolecular microparticles and methods of production and use
US5981719A (en)	1993-03-09	1999-11-09	Epic Therapeutics, Inc.	Macromolecular microparticles and methods of production and use
US5972326A (en) *	1995-04-18	1999-10-26	Galin; Miles A.	Controlled release of pharmaceuticals in the anterior chamber of the eye
US5612027A (en) *	1995-04-18	1997-03-18	Galin; Miles A.	Controlled release of miotic and mydriatic drugs in the anterior chamber
WO1997035561A1 (en)	1996-03-28	1997-10-02	The Board Of Trustees Of The University Of Illinois	Materials and methods for making improved liposome compositions
US6217886B1 (en)	1997-07-14	2001-04-17	The Board Of Trustees Of The University Of Illinois	Materials and methods for making improved micelle compositions
US6391336B1 (en) *	1997-09-22	2002-05-21	Royer Biomedical, Inc.	Inorganic-polymer complexes for the controlled release of compounds including medicinals
US6919076B1 (en)	1998-01-20	2005-07-19	Pericor Science, Inc.	Conjugates of agents and transglutaminase substrate linking molecules
US6958148B1 (en)	1998-01-20	2005-10-25	Pericor Science, Inc.	Linkage of agents to body tissue using microparticles and transglutaminase
CZ301969B6 (cs)	1998-04-29	2010-08-18	Novartis Ag	Farmaceutický prostredek pro stabilizaci acetylcholinových prípravku, pro lécení oka
DK172900B1 (da)	1998-12-18	1999-09-27	Per Julius Nielsen	Præparat samt kit til brug ved intraoculære operationer
AU2745700A (en)	1999-02-01	2000-08-18	Dermal Research Laboratories, Inc.	A pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
US6730065B1 (en) *	2000-09-15	2004-05-04	Ocularis Pharma, Inc.	Night vision composition
US6730691B1 (en)	2000-02-10	2004-05-04	Miles A. Galin	Uses of alpha adrenergic blocking agents
US20030086899A1 (en) *	2000-03-14	2003-05-08	Jafari Masoud R.	Chondroitin sulfate containing viscoelastics for use in treating joints
US7879824B2 (en)	2001-07-31	2011-02-01	Dermal Research Laboratories, Inc.	Methods of preventing or treating diseases and conditions using complex carbohydrates
US20030060447A1 (en) *	2002-04-24	2003-03-27	Mutlu Karakelle	Non-aspirating transitional viscoelastics for use in surgery
US7060297B2 (en)	2000-11-06	2006-06-13	Alcon, Inc.	Carrageenan viscoelastics for ocular surgery
WO2002060486A2 (en) *	2001-01-29	2002-08-08	Fresco Bernard B	Controlled release microsphere system for administration of drug to the eye
ATE547122T1 (de) *	2001-11-21	2012-03-15	Novartis Pharma Gmbh	Zusammensetzung zur stabilisierung von hyaluronsäure
CN103143022A (zh)	2002-07-30	2013-06-12	奥默罗斯公司	眼科冲洗液及方法
JP2004143155A (ja) *	2002-10-01	2004-05-20	Taisho Pharmaceut Co Ltd	眼科用剤
US20040167480A1 (en) *	2003-02-21	2004-08-26	Advanced Medical Optics, Inc.	Administration of multiple viscoelastic solutions with a multi-compartment syringe
US7993634B2 (en)	2004-04-30	2011-08-09	Allergan, Inc.	Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8722097B2 (en)	2004-04-30	2014-05-13	Allergan, Inc.	Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7799336B2 (en)	2004-04-30	2010-09-21	Allergan, Inc.	Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8673341B2 (en)	2004-04-30	2014-03-18	Allergan, Inc.	Intraocular pressure reduction with intracameral bimatoprost implants
US9498457B2 (en)	2004-04-30	2016-11-22	Allergan, Inc.	Hypotensive prostamide-containing biodegradable intraocular implants and related implants
CA2588449A1 (en) *	2004-11-24	2006-06-01	Therakine Corporation	An implant for intraocular drug delivery
JP2007308398A (ja) *	2006-05-17	2007-11-29	Chang Gung Memorial Hospital	目薬、及びその製造方法
US8450475B2 (en)	2008-08-04	2013-05-28	Allergan, Inc.	Hyaluronic acid-based gels including lidocaine
US20100247606A1 (en) *	2009-03-25	2010-09-30	Allergan, Inc.	Intraocular sustained release drug delivery systems and methods for treating ocular conditions
CA2757557C (en) *	2009-04-02	2017-06-27	Allergan, Inc.	Hair-like shaped hydrogels for soft tissue augmentation
US9114188B2 (en)	2010-01-13	2015-08-25	Allergan, Industrie, S.A.S.	Stable hydrogel compositions including additives
US20110172180A1 (en)	2010-01-13	2011-07-14	Allergan Industrie. Sas	Heat stable hyaluronic acid compositions for dermatological use
US8647659B2 (en) *	2010-01-22	2014-02-11	Allergan, Inc.	Intracameral sustained release therapeutic agent implants
AU2013201465B2 (en)	2012-10-24	2016-03-03	Rayner Intraocular Lenses Limited	Stable preservative-free mydriatic and anti-inflammatory solutions for injection
TWI705812B (zh)	2014-12-01	2020-10-01	奥默羅斯公司	用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
US10010502B2 (en)	2015-05-19	2018-07-03	Amorphex Therapeutics Llc	Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
KR102580933B1 (ko) *	2016-05-25	2023-09-19	싱가포르 헬스 서비시즈 피티이 엘티디	아트로핀-함유 수성 조성물
MX2019001877A (es)	2016-08-19	2019-09-13	Orasis Pharmaceuticals Ltd	Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas.
EP4066830A1 (en)	2018-04-24	2022-10-05	Allergan, Inc.	Use of pilocarpine hydrochloride for the treatment of ocular conditions
FR3086865B1 (fr) *	2018-10-04	2023-04-28	Matthieu Leconte	Preparation ophtalmique et lentille d'orthokeratologie pour l'inhibition, la prevention et/ou la limitation de la progression de la myopie

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4001388A (en) *	1973-06-14	1977-01-04	Alza Corporation	Ophthalmological bioerodible drug dispensing formulation
US4141973A (en) *	1975-10-17	1979-02-27	Biotrics, Inc.	Ultrapure hyaluronic acid and the use thereof
US4305927A (en) *	1979-02-05	1981-12-15	Alza Corporation	Method for the management of intraocular pressure
US4303637A (en) *	1980-04-04	1981-12-01	Alza Corporation	Medication indicated for ocular hypertension
IN163192B (is) *	1983-10-11	1988-08-20	Fidia Spa
US4911920A (en) *	1986-07-30	1990-03-27	Alcon Laboratories, Inc.	Sustained release, comfort formulation for glaucoma therapy
US4713244A (en) *	1985-08-16	1987-12-15	Bausch & Lomb Incorporated	Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
US4931279A (en) *	1985-08-16	1990-06-05	Bausch & Lomb Incorporated	Sustained release formulation containing an ion-exchange resin
US4668506A (en) *	1985-08-16	1987-05-26	Bausch & Lomb Incorporated	Sustained-release formulation containing and amino acid polymer
US4863457A (en) *	1986-11-24	1989-09-05	Lee David A	Drug delivery device
US5093126A (en) *	1987-09-26	1992-03-03	Alcon Laboratories, Inc.	Glaucoma formulations comprising an anionic, polysulfonic acid polymer having mucomimetic properties and a polystyrene sulfonic polymer
US4965253A (en) *	1987-10-14	1990-10-23	University Of Florida	Viscoelastic material for ophthalmic surgery
US4920104A (en) *	1988-05-16	1990-04-24	Medchem Products, Inc.	Sodium hyaluronate composition
US5098443A (en) *	1989-03-23	1992-03-24	University Of Miami	Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
US5007913A (en) *	1989-09-19	1991-04-16	Alcon Surgical, Inc.	Apparatus and method for implantation of intraocular lenses
US5318780A (en) *	1991-10-30	1994-06-07	Mediventures Inc.	Medical uses of in situ formed gels
SE9301422D0 (sv)	1993-04-28	1993-04-28	Kabi Pharmacia Ab	Method and means for inhibiting posterior capsule opacification
US5612027A (en) *	1995-04-18	1997-03-18	Galin; Miles A.	Controlled release of miotic and mydriatic drugs in the anterior chamber

1995
- 1995-04-18 US US08/423,703 patent/US5612027A/en not_active Expired - Lifetime
1996
- 1996-04-18 EA EA199700286A patent/EA000790B1/ru not_active IP Right Cessation
- 1996-04-18 MX MX9708043A patent/MX9708043A/es unknown
- 1996-04-18 PL PL96322820A patent/PL322820A1/xx unknown
- 1996-04-18 ES ES96912887T patent/ES2116950T1/es active Pending
- 1996-04-18 AU AU55557/96A patent/AU707013B2/en not_active Ceased
- 1996-04-18 CN CN96193352A patent/CN1181703A/zh active Pending
- 1996-04-18 EE EE9700286A patent/EE9700286A/xx unknown
- 1996-04-18 NZ NZ306875A patent/NZ306875A/xx unknown
- 1996-04-18 JP JP53191796A patent/JP3314085B2/ja not_active Expired - Fee Related
- 1996-04-18 EP EP96912887A patent/EP0822822A4/en not_active Withdrawn
- 1996-04-18 TR TR97/01192T patent/TR199701192T1/xx unknown
- 1996-04-18 CZ CZ973264A patent/CZ326497A3/cs unknown
- 1996-04-18 SK SK1402-97A patent/SK140297A3/sk unknown
- 1996-04-18 HU HU9802665A patent/HUP9802665A3/hu unknown
- 1996-04-18 DE DE0822822T patent/DE822822T1/de active Pending
- 1996-04-18 KR KR1019970707360A patent/KR100307685B1/ko not_active Expired - Fee Related
- 1996-04-18 GE GEAP19963920A patent/GEP20002231B/en unknown
- 1996-04-18 AP APAP/P/1997/001099A patent/AP850A/en active
- 1996-04-18 WO PCT/US1996/005395 patent/WO1996032951A1/en not_active Ceased
- 1996-04-18 BR BR9608441A patent/BR9608441A/pt not_active Application Discontinuation
- 1996-04-18 CA CA002216417A patent/CA2216417C/en not_active Expired - Fee Related
1997
- 1997-03-12 US US08/815,215 patent/US5766580A/en not_active Expired - Lifetime
- 1997-03-12 US US08/815,213 patent/US5759532A/en not_active Expired - Lifetime
- 1997-03-12 US US08/815,896 patent/US5965152A/en not_active Expired - Lifetime
- 1997-09-30 IS IS4572A patent/IS4572A/is unknown
- 1997-10-10 BG BG101960A patent/BG62598B1/bg unknown
- 1997-10-17 NO NO974808A patent/NO974808L/no not_active Application Discontinuation
- 1997-10-17 OA OA70111A patent/OA10744A/en unknown

Also Published As

Publication number	Publication date
PL322820A1 (en)	1998-02-16
NZ306875A (en)	1999-06-29
DE822822T1 (de)	1998-09-03
ES2116950T1 (es)	1998-08-01
KR19990007837A (ko)	1999-01-25
HUP9802665A3 (en)	2000-06-28
MX9708043A (es)	1998-03-31
JP3314085B2 (ja)	2002-08-12
CA2216417C (en)	2003-03-18
US5612027A (en)	1997-03-18
BG101960A (en)	1998-04-30
HUP9802665A2 (en)	1999-06-28
JPH10510293A (ja)	1998-10-06
AP850A (en)	2000-06-14
EP0822822A1 (en)	1998-02-11
NO974808D0 (no)	1997-10-17
KR100307685B1 (ko)	2001-12-12
EA000790B1 (ru)	2000-04-24
AP9701099A0 (en)	1997-10-31
EP0822822A4 (en)	2006-01-11
BG62598B1 (bg)	2000-03-31
BR9608441A (pt)	1999-02-17
CZ326497A3 (cs)	1998-09-16
US5759532A (en)	1998-06-02
AU5555796A (en)	1996-11-07
CN1181703A (zh)	1998-05-13
WO1996032951A1 (en)	1996-10-24
NO974808L (no)	1997-12-15
GEP20002231B (en)	2000-09-25
US5766580A (en)	1998-06-16
SK140297A3 (en)	1999-01-11
EE9700286A (et)	1998-06-15
TR199701192T1 (xx)	1998-02-21
US5965152A (en)	1999-10-12
AU707013B2 (en)	1999-07-01
IS4572A (is)	1997-09-30
EA199700286A1 (ru)	1998-04-30
CA2216417A1 (en)	1996-10-24

Publication	Publication Date	Title
US5965152A (en)	1999-10-12	Controlled release of miotic and mydriatic drugs in the anterior chamber
EP1027015B1 (en)	2005-02-09	Controlled release of pharmaceuticals in the anterior chamber of the eye
US20100036387A1 (en)	2010-02-11	Viscoelastic Composition for Surgical Procedures
EP1796628B1 (en)	2008-07-23	New viscoelastic composition comprising alginate and vitamin e tpgs or tpgsa
RU2147876C1 (ru)	2000-04-27	Фармацевтическая композиция для обезболивания в офтальмологии
RU2148404C1 (ru)	2000-05-10	Фармацевтическая композиция для медикаментозного расширения зрачка в офтальмологии
RU2284181C2 (ru)	2006-09-27	Фармацевтическая композиция для профилактики инфекции в офтальмологии "интрависк"
Genstler et al.	1983	Amvisc® in extracapsular cataract extraction
JPH0236128A (ja)	1990-02-06	眼内注射剤
JPH0640943A (ja)	1994-02-15	眼内手術用剤
HK1026839A (en)	2000-12-29	Controlled release of pharmaceuticals in the anterior chamber of the eye
Ponte et al.	1991	Intraocular dapiprazole for the reversal of mydriasis after extracapsular cataract extraction with intraocular lens implantation: Part II: Comparison with acetylcholine
MXPA99008634A (en)	2000-07-01	Controlled release of pharmaceuticals in the anterior chamber of the eye
HK1066163A1 (en)	2005-03-18	Viscoelastic ophthalmic compositions comprising hyaluronic acid and chondroitin sulphate
HK1066163B (en)	2006-04-13	Viscoelastic ophthalmic compositions comprising hyaluronic acid and chondroitin sulphate